Uneedle sets a new standard for reliable intradermal administration from 0.1 to 1.0 mL

Intradermal | Our lead product Bella-mu makes intradermal administration up to 1 mL easy to learn when comparing to Mantoux, for companies developing cancer vaccines that benefit from enhanced immune responses, reduced antigen required, ease of administration and increased patient compliance. For example vaccines based on neoantigens, whole-tumor-cells, mRNA, DNA, peptides, viral vectors or dendritic cells.

Intraocular | Uneedle Ophthalmics developes Bella-Vue facilitating suprachoroidal injections to deliver small molecules or biologics to the back of the eye. For example for companies developing ophthalmic therapies involving the retina or the macula, e.g. age-related macular degeneration (AMD), diabetic retinopathy, retinal detachment, retinitis pigmentosa or macular edema.

As a legal manufacturer of intradermic needles, Uneedle provides easy to learn and reliable injection into superficial tissues.
The Uneedle organisation is full scope ISO13485 certified for design and manufacturing of silicon microneedles.
Our expertise is to design and manufacture needles that are very short, sharp and precise, based on proprietary technology that is CE marked and FDA approved, making use of innovative semiconductor manufacturing processes in our in-house GMP compliant  manufacturing site in The Netherlands (EU)

 Learn more

Our mission is to realise a superior, proprietary silicon microneedle platform by co-developing intradermal & suprachoroidal administered medicinal products with pharmaceutical partners.